Weather ALERT: We are actively monitoring the weather in our area to ensure patient and staff safety. Please see our NEWS Section and social media outlets for updates throughout the coming days. Arlington Office Patients: We apologize for any inconvenience. Currently our phones are down at our Arlington office. We hope for resolution soon. If you need to reach the Arlington office, please call our main number. Thank you for your patience.
A personalized, proprietary cancer vaccine composed of sterile, irradiated, non-dividing, live colon cancer cells obtained from an individual after tumor resection, with potential immunoactivating and antineoplastic activities. Upon intradermal administration, the autologous colon cancer cell vaccine activates the immune system and elicits a cytotoxic T-lymphocytic (CTL) response against the residual colon cancer cells, which results in tumor cell death. This may prevent cancer recurrence. According to the vaccination schedule, the first two out of the four doses are co-administered with the immunoadjuvant bacillus Calmette-Guerin (BCG), which is an attenuated strain of Mycobacterium bovis that non-specifically enhances the immune response. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
